title: Magnesium sulfate administration in subarachnoid hemorrhage.
abstract: Magnesium offers theoretic vascular and neuroprotective benefits for patients with subarachnoid hemorrhage. An electronic literature search was conducted to identify original research studies describing intravenous magnesium treatment in patients with SAH published in English between January 1990 and October 2010. Seventeen articles were identified and reviewed, including one phase III randomized-controlled clinical trial and six phase II randomized-controlled trials. Study quality was low for most of the included studies, with the phase III trial considered to be of moderate quality. Due to inconsistently reported benefits and the occurrence of side effects, phase II data suggested that intravenous magnesium for SAH provided either no overall net benefit or uncertain trade-offs. Benefit was likewise not supported in the single phase III clinical trial.
authors: Department of Neurology, Baylor College of Medicine, 6501 Fannin St, NB302, Houston, TX 77030, USA, jisuarez@bcm.edu
authors: Jose I
authors: JI
authors: Suarez
mesh_terms: D000208:Acute Disease; D000927:Anticonvulsants / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy / Q000209:etiology; D003422:Critical Care / Q000379:methods; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D013345:Subarachnoid Hemorrhage / Q000150:complications / Q000188:drug therapy*; D020301:Vasospasm, Intracranial / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000927:Anticonvulsants; D018696:Neuroprotective Agents; D008278:Magnesium Sulfate